U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07497282) titled 'Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis' on Jan. 19.
Brief Summary: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation of the joints, leading to pain, swelling, disability, and reduced quality of life. Current therapies, although effective, may have limited efficacy or tolerability in some patients. Biological DMARDs are often associated with adverse effects, including increased risk of serious infections and heart failure. Long-term use may also increase the risk of malignancies. These limitations, together with their high cost. Venlafaxine, a serotonin-norepinephrine ...